Retractable Technologies (RVP)
XASE:RVP
Want to see RVP full AI Analyst Report?
RVP Stock Chart & Stats
$0.73
>-$0.01(-0.49%)
At close: 4:00 PM EST
$0.73
>-$0.01(-0.49%)
Day’s Range― - ―
52-Week Range$0.60 - $1.14
Previous CloseN/A
Volume39.25K
Average Volume (3M)153.51K
Market Cap
$18.91M
Enterprise Value$16.37M
Total Cash (Recent Filing)$36.97M
Total Debt (Recent Filing)$365.28K
Price to Earnings (P/E)―
Beta0.42
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding29,937,159
10 Day Avg. Volume341,920
30 Day Avg. Volume153,511
Financial Highlights & Ratios
PEG Ratio-0.25
Price to Book (P/B)0.31
Price to Sales (P/S)0.60
P/FCF Ratio-3.04
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue0.43
Enterprise Value/Gross Profit347.91
Enterprise Value/Ebitda-1.85
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low-Leverage Balance SheetConsistently low leverage gives the company durable financial flexibility to absorb ongoing losses and pursue restructuring or inventory spending without immediately needing high-cost financing. This reduces short-term solvency risk and supports longer runway for operational recovery if cash burn eases.
Niche Safety-Device FranchiseA focused product portfolio centered on retractable safety syringes addresses persistent regulatory and institutional demand to cut needlestick injuries. This creates structural, recurring per-unit demand from healthcare providers and group purchasers, supporting steady long-term product relevance and aftermarket consumable sales.
Top-Line Recovery & International GrowthRecent revenue growth and outsized international expansion indicate the business retains sales traction outside pandemic distortions. Diversifying geography can stabilize top-line cyclicality, expand addressable markets, and provide a platform for sustainable unit-volume recovery if margins and cost structure are managed.
Bears Say
Multi-Year Losses & Revenue CollapseA multi-year shift from profitability to sustained losses and a dramatic revenue decline erode core earnings power and operating scale. This weakens pricing leverage, damages supplier/customer relationships, and requires structural fixes to restore gross margins and long-run viability if not reversed.
Negative Cash Flow & Tight LiquidityPersistent operating and free cash burn with very low cash balances materially shorten financial runway. Limited internal cash generation constrains investments in production, sales, and regulatory compliance, and heightens need for external financing or asset actions that could dilute shareholders or disrupt operations.
Tariff & Operational Cost PressuresMaterial tariff expenses and recent restructuring signal sustained cost and supply-chain headwinds. Tariff-driven margin pressure and cutbacks to headcount can impair capacity, product quality, and customer service, making it harder to rebuild volumes and profitability over a multi-month to multi-year timeframe.
Retractable Technologies News
RVP FAQ
What was Retractable Technologies’s price range in the past 12 months?
Retractable Technologies lowest stock price was $0.60 and its highest was $1.14 in the past 12 months.
What is Retractable Technologies’s market cap?
Retractable Technologies’s market cap is $18.91M.
When is Retractable Technologies’s upcoming earnings report date?
Retractable Technologies’s upcoming earnings report date is May 18, 2026 which is in 16 days.
How were Retractable Technologies’s earnings last quarter?
Retractable Technologies released its earnings results on Mar 27, 2026. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.08.
Is Retractable Technologies overvalued?
According to Wall Street analysts Retractable Technologies’s price is currently Overvalued.
Does Retractable Technologies pay dividends?
Retractable Technologies does not currently pay dividends.
What is Retractable Technologies’s EPS estimate?
Retractable Technologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Retractable Technologies have?
Retractable Technologies has 29,937,159 shares outstanding.
What happened to Retractable Technologies’s price movement after its last earnings report?
Retractable Technologies reported an EPS of -$0.08 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.836%.
Which hedge fund is a major shareholder of Retractable Technologies?
Currently, no hedge funds are holding shares in RVP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Retractable Technologies
Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally. It offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes. The company distributes its products through general line and specialty distributors, as well as through international distributors; and a direct marketing network. Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas.
Technical Analysis
Orasure Technologies
―
Stereotaxis
―
Milestone Scientific
―
Sanara MedTech
―
Sharps Technology, Inc.
―
Ownership Overview
55.66% Insiders
2.55% Mutual Funds
0.18% Other Institutional Investors
39.67% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---